
Home » Pharmos doses first patients in phase IIa gout trial
Pharmos doses first patients in phase IIa gout trial
January 13, 2012
Pharmos has dosed its first U.S. patients with its compound levotofisopam (S-tofisopam) to treat hyperuricemia and gout. As a phase IIa proof-of-concept trial, the trial is designed to assess the safety and efficiacy of levotofisopam as a uric acid-lowering agent.
This trial follows two phase I studies that were completed by Vela Pharmaceuticals, which merged with Pharmos in 2006. These studies, conducted in the United Kingdom and the Netherlands, showed levotofisopam was associated with a large and rapid reduction in serum uric acid values.
Levotofisopam is the S-entantiomer of the racemic mixture RS-tofisopam, a well-tolerated, effective, nonsedating agent used for the treatment of disorders associated with stress or autonomic instability.
Pharmos said once this clinical trial is completed it plans to seek a partner to develop levotofisopam for the treatment of gout.
Upcoming Events
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May